Global burden of transfusion in sickle cell disease

Kaur, 2013, An overview on sickle cell disease profile, Asian J Pharm Clin Res, 6, 25 Herrick, 2001, Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910, Yale J Biol Med, 74, 179 Williams, 2018, Sickle cell anemia and its phenotypes, Annu Rev Genom Hum Genet, 19, 113, 10.1146/annurev-genom-083117-021320 World Health Assembly, 2006 Han, 2021, Indications for transfusion in the management of sickle cell disease, Hematol Am Soc Hematol Educ Program, 2021, 696, 10.1182/hematology.2021000307 Seck, 2022, Transfusion practice, post-transfusion complications and risk factors in sickle cell disease in Senegal, West Africa, Mediterr J Hematol Infect Dis, 14, 10.4084/MJHID.2022.004 Gyamfi, 2021, Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: a systematic review of randomized controlled trials, PLoS One, 16, 10.1371/journal.pone.0246700 Wastnedge, 2018, The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis, J Glob Health, 8, 10.7189/jogh.08.021103 Steinberg, 2008, Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches, ScientificWorldJournal, 8, 1295, 10.1100/tsw.2008.157 Ashley-Koch, 2000, Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review, Am J Epidemiol, 151, 839, 10.1093/oxfordjournals.aje.a010288 Kato, 2018, Sickle cell disease, Nat Rev Dis Prim, 4, 18010, 10.1038/nrdp.2018.10 Therrell, 2020, Empowering newborn screening programs in African countries through establishment of an international collaborative effort, J Community Genet, 11, 253, 10.1007/s12687-020-00463-7 Piel, 2013, Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions, PLoS Med, 10, 10.1371/journal.pmed.1001484 Grosse, 2011, Sickle cell disease in Africa: a neglected cause of early childhood mortality, Am J Prev Med, 41, S398, 10.1016/j.amepre.2011.09.013 Telfer, 2007, Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London, Haematologica, 92, 905, 10.3324/haematol.10937 Quinn, 2010, Improved survival of children and adolescents with sickle cell disease, Blood, 115, 3447, 10.1182/blood-2009-07-233700 Piel, 2013, Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates, Lancet, 381, 142, 10.1016/S0140-6736(12)61229-X United Nations DoEaSA, Population Division (2022). World Population Prospects 2022, Online Edition. Hassell, 2010, Population estimates of sickle cell disease in the U.S, Am J Prev Med, 38, S512, 10.1016/j.amepre.2009.12.022 Iolascon, 2019, EHA research roadmap on hemoglobinopathies and thalassemia: an update, Hemasphere, 3, 10.1097/HS9.0000000000000208 Aguilar Martinez, 2014, Haemoglobinopathies in Europe: health & migration policy perspectives, Orphanet J Rare Dis, 9, 97, 10.1186/1750-1172-9-97 Powell, 1992, Acute splenic sequestration crisis in sickle cell disease: early detection and treatment, J Pedia Surg, 27, 215, 10.1016/0022-3468(92)90315-X Hoppe, 2013, Prenatal and newborn screening for hemoglobinopathies, Int J Lab Hematol, 35, 297, 10.1111/ijlh.12076 Minkovitz, 2016, Newborn screening programs and sickle cell disease: a public health services and systems approach, Am J Prev Med, 51, S39, 10.1016/j.amepre.2016.02.019 Kuznik, 2016, Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis, BMC Health Serv Res, 16, 304, 10.1186/s12913-016-1572-6 Robitaille, 2006, Newborn screening for sickle cell disease: a 1988-2003 Quebec experience, Paediatr Child Health, 11, 223, 10.1093/pch/11.4.223 The National Institute for Health and Care Excellence. Sickle cell disease: What are the complications of sickle cell disease? 2021. p. March 02 2023. Veluswamy, 2019, Vaso-Occlusion in sickle cell disease: is autonomic dysregulation of the microvasculature the trigger?, J Clin Med, 8 Moerdler, 2018, New insights into the pathophysiology and development of novel therapies for sickle cell disease, Hematol Am Soc Hematol Educ Program, 2018, 493, 10.1182/asheducation-2018.1.493 Sundd, 2019, Pathophysiology of sickle cell disease, Annu Rev Pathol, 14, 263, 10.1146/annurev-pathmechdis-012418-012838 Chou, 2013, Transfusion therapy for sickle cell disease: a balancing act, Hematology, 2013, 439, 10.1182/asheducation-2013.1.439 Mehari, 2016, Chronic pulmonary complications of sickle cell disease, Chest, 149, 1313, 10.1016/j.chest.2015.11.016 Vichinsky, 2000, Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group, N Engl J Med, 342, 1855, 10.1056/NEJM200006223422502 Kanter, 2013, Management of sickle cell disease from childhood through adulthood, Blood Rev, 27, 279, 10.1016/j.blre.2013.09.001 Ballas, 2010, Definitions of the phenotypic manifestations of sickle cell disease, Am J Hematol, 85, 6, 10.1002/ajh.21550 Gladwin, 2004, Pulmonary hypertension as a risk factor for death in patients with sickle cell disease, N Engl J Med, 350, 886, 10.1056/NEJMoa035477 DeBaun, 2011, Secondary prevention of overt strokes in sickle cell disease: therapeutic strategies and efficacy, Hematol Am Soc Hematol Educ Program, 2011, 427, 10.1182/asheducation-2011.1.427 Hulbert, 2006, Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia, J Pedia, 149, 710, 10.1016/j.jpeds.2006.06.037 Powars, 1978, The natural history of stroke in sickle cell disease, Am J Med, 65, 461, 10.1016/0002-9343(78)90772-6 Migotsky, 2022, Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and L-glutamine, Pharm (Basel), 10 Brandow, 2010, Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities, Expert Rev Hematol, 3, 255, 10.1586/ehm.10.22 National Heart LaBI. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report. 2014. Chou, 2020, American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support, Blood Adv, 4, 327, 10.1182/bloodadvances.2019001143 World Health Organization. Blood safety and availability. Available at: https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability (Accessed 23 June 23 2022). Wade, 2022, Procedural adverse events in pediatric patients with sickle cell disease undergoing chronic automated red cell exchange, Transfusion, 62, 584, 10.1111/trf.16807 Sarode, 2011, Advantages of isovolemic hemodilution-red cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients, J Clin Apher, 26, 200, 10.1002/jca.20294 Rees, 2018, How I manage red cell transfusions in patients with sickle cell disease, Br J Haematol, 180, 607, 10.1111/bjh.15115 DeBaun, 2014, Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia, N Engl J Med, 371, 699, 10.1056/NEJMoa1401731 Biller, 2018, Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB, Transfusion, 58, 1965, 10.1111/trf.14806 Lee, 2006, Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results, Blood, 108, 847, 10.1182/blood-2005-10-009506 Nouraie, 2015, Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis, Transfusion, 55, 2331, 10.1111/trf.13155 Kalff, 2010, The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults, Br J Haematol, 149, 768, 10.1111/j.1365-2141.2010.08150.x Vichinsky, 1995, A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The preoperative transfusion in sickle cell disease study group, N Engl J Med, 333, 206, 10.1056/NEJM199507273330402 Alvarez, 2013, Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial, Am J Hematol, 88, 932, 10.1002/ajh.23547 Ware, 2012, Stroke with transfusions changing to hydroxyurea (SWiTCH), Blood, 119, 3925, 10.1182/blood-2011-11-392340 Coates, 2019, Iron overload in transfusion-dependent patients, Hematology, 2019, 337, 10.1182/hematology.2019000036 Strobel, 2008, Hemolytic Transfusion Reactions, Transfus Med Hemother, 35, 346, 10.1159/000154811 Vekeman, 2016, Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia, J Med Econ, 19, 292, 10.3111/13696998.2015.1117979 Coates, 2017, How we manage iron overload in sickle cell patients, Br J Haematol, 177, 703, 10.1111/bjh.14575 Chaudhary, 2013, Deferasirox: appraisal of safety and efficacy in long-term therapy, J Blood Med, 4, 101 Armstrong, 2013, Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs, J Med Econ, 16, 10, 10.3111/13696998.2012.723081 Tsouana, 2015, Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network, Eur J Haematol, 94, 336, 10.1111/ejh.12435 Jenny, 2017, Access to safe blood in low-income and middle-income countries: lessons from India, BMJ Glob Health, 2, 10.1136/bmjgh-2016-000167 Custer, 2018, Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop, Transfusion, 58, 1307, 10.1111/trf.14598 WHO Guidelines Approved by the Guidelines Review Committee. Screening Donated Blood for Transfusion-Transmissible Infections: Recommendations. Geneva: World Health Organization; 2009. Adewoyin, 2017, Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance, Afr Health Sci, 17, 255, 10.4314/ahs.v17i1.31 Misra, 2017, A Phase Ib open label, randomized, safety study of SANGUINATE in patients with sickle cell anemia, Rev Bras Hematol Hemoter, 39, 20, 10.1016/j.bjhh.2016.08.004 Inusa, 2019, Geographic differences in phenotype and treatment of children with sickle cell anemia from the multinational DOVE study, J Clin Med, 8 Ofakunrin, 2021, Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria, Afr Health Sci, 21, 765, 10.4314/ahs.v21i2.36 Ballas, 2009, The cost of health care for patients with sickle cell disease, Am J Hematol, 84, 320, 10.1002/ajh.21443 Wayne, 2000, Financial analysis of chronic transfusion for stroke prevention in sickle cell disease, Blood, 96, 2369, 10.1182/blood.V96.7.2369 Baldwin, 2022, Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis, Pharm Open, 6, 469 Hilliard, 2018, Red blood cell transfusion therapy for sickle cell patients with frequent painful events, Pedia Blood Cancer, 65, 10.1002/pbc.27423 Amarachukwu, 2022, Economic burden and catastrophic cost among people living with sickle cell disease, attending a tertiary health institution in south-east zone, Nigeria, PLoS One, 17, 10.1371/journal.pone.0272491 Alwaheed, 2022, Delayed hemolytic transfusion reaction in sickle cell disease: a case series, Am J Case Rep, 23 Balbuena-Merle, 2019, Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease, Transfus Clin Biol, 26, 112, 10.1016/j.tracli.2019.02.003 Tormey, 2019, Transfusion-related red blood cell alloantibodies: induction and consequences, Blood, 133, 1821, 10.1182/blood-2018-08-833962 Hendrickson, 2020, Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction, Ann Blood, 5 Yazdanbakhsh, 2012, Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management, Blood, 120, 528, 10.1182/blood-2011-11-327361 Vichinsky, 1990, Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood, N Engl J Med, 322, 1617, 10.1056/NEJM199006073222301 Rosse, 1990, Transfusion and alloimmunization in sickle cell disease. The cooperative study of sickle cell disease, Blood, 76, 1431, 10.1182/blood.V76.7.1431.1431 Murao, 2005, Risk factors for alloimmunization by patients with sickle cell disease, Braz J Med Biol Res, 38, 675, 10.1590/S0100-879X2005000500004 Wahl, 2012, Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions, Transfusion, 52, 2671, 10.1111/j.1537-2995.2012.03659.x Coleman, 2019, Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions, Transfusion, 59, 2282, 10.1111/trf.15328 Wayne, 1993, Transfusion management of sickle cell disease, Blood, 81, 1109, 10.1182/blood.V81.5.1109.bloodjournal8151109 Serjeant, 2016, Management of sickle cell disease: challenges and risks of transfusion, Int J Clin Transfus Med, 4, 109, 10.2147/IJCTM.S96918 Moreira Júnior, 1996, Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil, Am J Hematol, 52, 197, 10.1002/(SICI)1096-8652(199607)52:3<197::AID-AJH11>3.0.CO;2-D Olujohungbe, 2001, Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom, Br J Haematol, 113, 661, 10.1046/j.1365-2141.2001.02819.x Chou, 2013, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors, Blood, 122, 1062, 10.1182/blood-2013-03-490623 Pirenne, 2021, How to avoid the problem of erythrocyte alloimmunization in sickle cell disease, Hematol Am Soc Hematol Educ Program, 2021, 689, 10.1182/hematology.2021000306 Davis, 2017, Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects, Br J Haematol, 176, 179, 10.1111/bjh.14346 Compernolle, 2018, Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline, Transfusion, 58, 1555, 10.1111/trf.14611 Desai, 2015, Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease, Am J Hematol, 90, 691, 10.1002/ajh.24051 Hod, 2010, Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation, Blood, 115, 4284, 10.1182/blood-2009-10-245001 Donadee, 2011, Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion, Circulation, 124, 465, 10.1161/CIRCULATIONAHA.110.008698 Xiong, 2011, Red blood cell microparticles show altered inflammatory chemokine binding and release ligand upon interaction with platelets, Transfusion, 51, 610, 10.1111/j.1537-2995.2010.02861.x Ackfeld, 2022, Blood transfusion reactions-a comprehensive review of the literature including a swiss perspective, J Clin Med, 11 Goel, 2019, Noninfectious transfusion-associated adverse events and their mitigation strategies, Blood, 133, 1831, 10.1182/blood-2018-10-833988 Rajesh, 2015, Effects of prestorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to red blood cells in a tertiary care hospital, Ann Med Health Sci Res, 5, 185, 10.4103/2141-9248.157498 Geiger, 2007, Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice?, Transfus Med Rev, 21, 1, 10.1016/j.tmrv.2006.09.001 Shah, 2012, Complications of implantable venous access devices in patients with sickle cell disease, Am J Hematol, 87, 224, 10.1002/ajh.22230 Otrock, 2018, Vascular access for red blood cell exchange, Transfusion, 58, 569, 10.1111/trf.14495 Salawu, 2022, Totally implantable venous access ports and associated complications in sub-Saharan Africa: a single-centre retrospective analysis, Ecancermedicalscience, 16, 1389, 10.3332/ecancer.2022.1389 Beverung, 2015, Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy, Am J Hematol, 90, 139, 10.1002/ajh.23877 Maxwell, 2019, Health-related quality of life in children with sickle cell disease undergoing chronic red cell transfusion therapy, J Pedia Hematol Oncol, 41, 307, 10.1097/MPH.0000000000001376 Hawkins, 2020, Patient and family experience with chronic transfusion therapy for sickle cell disease: a qualitative study, BMC Pedia, 20, 172, 10.1186/s12887-020-02078-w Carden, 2019, Emerging disease-modifying therapies for sickle cell disease, Haematologica, 104, 1710, 10.3324/haematol.2018.207357 DʼAlessandro, 2020, Hypoxic storage of red blood cells improves metabolism and post-transfusion recovery, Transfusion, 60, 786, 10.1111/trf.15730 Yoshida, 2019, Red blood cell storage lesion: causes and potential clinical consequences, Blood Transfus, 17, 27